In HER2-positive (IHC 3+) breast cancer patient-derived xenograft models named MAXF1322 and MAXF1162, SYD985 dose dependently reduced tumor growth, whereas high dose trastuzumab did not show any antitumor activity. This evidence concerns the gene ERBB2 and breast carcinoma.